<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title38.html">
                                    Title 38
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/38CFR4.html">Part 4
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  4.118  Schedule of ratings--skin.
                            </h3>
                            <p class="depth0">A veteran whose scars were rated by VA under a prior version of diagnostic codes 7800, 7801, 7802, 7803, 7804, or 7805,

as in effect before October 23, 2008, may request review under diagnostic codes 7800, 7801, 7802, 7804, and 7805, irrespective of whether his or her disability has worsened since the last review. VA will review that veteran's disability rating to determine whether the veteran may be entitled to a higher disability rating under diagnostic codes 7800, 7801, 7802, 7804, and 7805. A request for review pursuant to this rulemaking will be treated as a claim for an increased rating for purposes of determining the effective date of an increased rating awarded as a result of such review; however, in no case will the award be effective before October 23, 2008.
------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------7800 Burn scar(s) of the head, face, or neck; scar(s) of the</p><p class="depth0">head, face, or neck due to other causes; or other disfigurement</p><p class="depth0">of the head, face, or neck:</p><p class="depth0">With visible or palpable tissue loss and either gross             80</p><p class="depth0">distortion or asymmetry of three or more features or paired</p><p class="depth0">sets of features (nose, chin, forehead, eyes (including</p><p class="depth0">eyelids), ears (auricles), cheeks, lips), or; with six or</p><p class="depth0">more characteristics of disfigurement......................</p><p class="depth0">With visible or palpable tissue loss and either gross             50</p><p class="depth0">distortion or asymmetry of two features or paired sets of</p><p class="depth0">features (nose, chin, forehead, eyes (including eyelids),</p><p class="depth0">ears (auricles), cheeks, lips), or; with four or five</p><p class="depth0">characteristics of disfigurement...........................</p><p class="depth0">With visible or palpable tissue loss and either gross             30</p><p class="depth0">distortion or asymmetry of one feature or paired set of</p><p class="depth0">features (nose, chin, forehead, eyes (including eyelids),</p><p class="depth0">ears (auricles), cheeks, lips), or; with two or three</p><p class="depth0">characteristics of disfigurement...........................</p><p class="depth0">With one characteristic of disfigurement....................      10</p><p class="depth0">Note (1):The 8 characteristics of disfigurement, for</p><p class="depth0">purposes of evaluation under Sec.   4.118, are:</p><p class="depth0">Scar 5 or more inches (13 or more cm.) in length.</p><p class="depth0">Scar at least one-quarter inch (0.6 cm.) wide at widest</p><p class="depth0">part.</p><p class="depth0">Surface contour of scar elevated or depressed on palpation.</p><p class="depth0">Scar adherent to underlying tissue.</p><p class="depth0">Skin hypo-or hyper-pigmented in an area exceeding six square</p><p class="depth0">inches (39 sq. cm.).</p><p class="depth0">Skin texture abnormal (irregular, atrophic, shiny, scaly,</p><p class="depth0">etc.) in an area exceeding six square inches (39 sq. cm.).</p><p class="depth0">Underlying soft tissue missing in an area exceeding six</p><p class="depth0">square inches (39 sq. cm.).</p><p class="depth0">Skin indurated and inflexible in an area exceeding six</p><p class="depth0">square inches (39 sq. cm.).</p><p class="depth0">Note (2): Rate tissue loss of the auricle under DC 6207</p><p class="depth0">(loss of auricle) and anatomical loss of the eye under DC</p><p class="depth0">6061 (anatomical loss of both eyes) or DC 6063 (anatomical</p><p class="depth0">loss of one eye), as appropriate.</p><p class="depth0">Note (3): Take into consideration unretouched color</p><p class="depth0">photographs when evaluating under these criteria.</p><p class="depth0">Note (4): Separately evaluate disabling effects other than</p><p class="depth0">disfigurement that are associated with individual scar(s)</p><p class="depth0">of the head, face, or neck, such as pain, instability, and</p><p class="depth0">residuals of associated muscle or nerve injury, under the</p><p class="depth0">appropriate diagnostic code(s) and apply Sec.   4.25 to</p><p class="depth0">combine the evaluation(s) with the evaluation assigned</p><p class="depth0">under this diagnostic code.</p><p class="depth0">Note (5): The characteristic(s) of disfigurement may be</p><p class="depth0">caused by one scar or by multiple scars; the</p><p class="depth0">characteristic(s) required to assign a particular</p><p class="depth0">evaluation need not be caused by a single scar in order to</p><p class="depth0">assign that evaluation.7801 Burn scar(s) or scar(s) due to other causes, not of the</p><p class="depth0">head, face, or neck, that are deep and nonlinear:</p><p class="depth0">Area or areas of 144 square inches (929 sq. cm.) or greater.      40</p><p class="depth0">Area or areas of at least 72 square inches (465 sq. cm.) but      30</p><p class="depth0">less than 144 square inches (929 sq. cm.)..................</p><p class="depth0">Area or areas of at least 12 square inches (77 sq. cm.) but       20</p><p class="depth0">less than 72 square inches (465 sq. cm.)...................</p><p class="depth0">Area or areas of at least 6 square inches (39 sq. cm.) but        10</p><p class="depth0">less than 12 square inches (77 sq. cm.)....................</p><p class="depth0">Note (1): A deep scar is one associated with underlying soft</p><p class="depth0">tissue damage.</p><p class="depth0">Note (2): If multiple qualifying scars are present, or if a</p><p class="depth0">single qualifying scar affects more than one extremity, or</p><p class="depth0">a single qualifying scar affects one or more extremities</p><p class="depth0">and either the anterior portion or posterior portion of the</p><p class="depth0">trunk, or both, or a single qualifying scar affects both</p><p class="depth0">the anterior portion and the posterior portion of the</p><p class="depth0">trunk, assign a separate evaluation for each affected</p><p class="depth0">extremity based on the total area of the qualifying scars</p><p class="depth0">that affect that extremity, assign a separate evaluation</p><p class="depth0">based on the total area of the qualifying scars that affect</p><p class="depth0">the anterior portion of the trunk, and assign a separate</p><p class="depth0">evaluation based on the total area of the qualifying scars</p><p class="depth0">that affect the posterior portion of the trunk. The</p><p class="depth0">midaxillary line on each side separates the anterior and</p><p class="depth0">posterior portions of the trunk. Combine the separate</p><p class="depth0">evaluations under Sec.   4.25. Qualifying scars are scars</p><p class="depth0">that are nonlinear, deep, and are not located on the head,</p><p class="depth0">face, or neck.7802 Burn scar(s) or scar(s) due to other causes, not of the</p><p class="depth0">head, face, or neck, that are superficial and nonlinear:</p><p class="depth0">Area or areas of 144 square inches (929 sq. cm.) or greater.      10</p><p class="depth0"></p><p class="depth0">Note (1): A superficial scar is one not associated with</p><p class="depth0">underlying soft tissue damage</p><p class="depth0">Note (2): If multiple qualifying scars are present, or if a</p><p class="depth0">single qualifying scar affects more than one extremity, or</p><p class="depth0">a single qualifying scar affects one or more extremities</p><p class="depth0">and either the anterior portion or posterior portion of the</p><p class="depth0">trunk, or both, or a single qualifying scar affects both</p><p class="depth0">the anterior portion and the posterior portion of the</p><p class="depth0">trunk, assign a separate evaluation for each affected</p><p class="depth0">extremity based on the total area of the qualifying scars</p><p class="depth0">that affect that extremity, assign a separate evaluation</p><p class="depth0">based on the total area of the qualifying scars that affect</p><p class="depth0">the anterior portion of the trunk, and assign a separate</p><p class="depth0">evaluation based on the total area of the qualifying scars</p><p class="depth0">that affect the posterior portion of the trunk. The</p><p class="depth0">midaxillary line on each side separates the anterior and</p><p class="depth0">posterior portions of the trunk. Combine the separate</p><p class="depth0">evaluations under Sec.   4.25. Qualifying scars are scars</p><p class="depth0">that are nonlinear, superficial, and are not located on the</p><p class="depth0">head, face, or neck.7804 Scar(s), unstable or painful:..............................</p><p class="depth0">Five or more scars that are unstable or painful.............      30</p><p class="depth0">Three or four scars that are unstable or painful............      20</p><p class="depth0">One or two scars that are unstable or painful...............      10</p><p class="depth0">Note (1): An unstable scar is one where, for any reason,</p><p class="depth0">there is frequent loss of covering of skin over the scar.</p><p class="depth0">Note (2): If one or more scars are both unstable and</p><p class="depth0">painful, add 10 percent to the evaluation that is based on</p><p class="depth0">the total number of unstable or painful scars</p><p class="depth0">Note (3): Scars evaluated under diagnostic codes 7800, 7801,</p><p class="depth0">7802, or 7805 may also receive an evaluation under this</p><p class="depth0">diagnostic code, when applicable7805 Scars, other (including linear scars) and other effects of</p><p class="depth0">scars evaluated under diagnostic codes 7800, 7801, 7802, and</p><p class="depth0">7804:</p><p class="depth0">Evaluate any disabling effect(s) not considered in a rating</p><p class="depth0">provided under diagnostic codes 7800-04 under an</p><p class="depth0">appropriate diagnostic code................................7806 Dermatitis or eczema.</p><p class="depth0">More than 40 percent of the entire body or more than 40           60</p><p class="depth0">percent of exposed areas affected, or; constant or near-</p><p class="depth0">constant systemic therapy such as corticosteroids or other</p><p class="depth0">immunosuppressive drugs required during the past 12-month</p><p class="depth0">period.....................................................</p><p class="depth0">20 to 40 percent of the entire body or 20 to 40 percent of        30</p><p class="depth0">exposed areas affected, or; systemic therapy such as</p><p class="depth0">corticosteroids or other immunosuppressive drugs required</p><p class="depth0">for a total duration of six weeks or more, but not</p><p class="depth0">constantly, during the past 12-month period................</p><p class="depth0">At least 5 percent, but less than 20 percent, of the entire       10</p><p class="depth0">body, or at least 5 percent, but less than 20 percent, of</p><p class="depth0">exposed areas affected, or; intermittent systemic therapy</p><p class="depth0">such as corticosteroids or other immunosuppressive drugs</p><p class="depth0">required for a total duration of less than six weeks during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Less than 5 percent of the entire body or less than 5              0</p><p class="depth0">percent of exposed areas affected, and; no more than</p><p class="depth0">topical therapy required during the past 12-month period...</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7807 American (New World) leishmaniasis (mucocutaneous,</p><p class="depth0">espundia):</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis</p><p class="depth0">(DC 7806), depending upon the predominant disability.......</p><p class="depth0">Note: Evaluate non-cutaneous (visceral) leishmaniasis under</p><p class="depth0">DC 6301 (visceral leishmaniasis).7808 Old World leishmaniasis (cutaneous, Oriental sore):</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's, 7801, 7802, 7803, 7804, or 7805), or</p><p class="depth0">dermatitis (DC 7806), depending upon the predominant</p><p class="depth0">disabililty................................................</p><p class="depth0">Note: Evaluate non-cutaneous (visceral) leishmaniasis under</p><p class="depth0">DC 6301 (visceral leishmaniasis).7809 Discoid lupus erythematosus or subacute cutaneous lupus</p><p class="depth0">erythematosus:</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis</p><p class="depth0">(DC 7806), depending upon the predominant disability. Do</p><p class="depth0">not combine with ratings under DC 6350.....................7811 Tuberculosis luposa (lupus vulgaris), active or inactive:</p><p class="depth0">Rate under Sec.  Sec.   4.88c or 4.89, whichever is</p><p class="depth0">appropriate................................................7813 Dermatophytosis (ringworm: of body, tinea corporis; of</p><p class="depth0">head, tinea capitis; of feet, tinea pedis; of beard area, tinea</p><p class="depth0">barbae; of nails, tinea unguium; of inguinal area (jock itch),</p><p class="depth0">tinea cruris):</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis</p><p class="depth0">(DC 7806), depending upon the predominant disability.......7815 Bullous disorders (including pemphigus vulgaris, pemphigus</p><p class="depth0">foliaceous, bullous pemphigoid, dermatitis herpetiformis,</p><p class="depth0">epidermolysis bullosa acquisita, benign chronic familial</p><p class="depth0">pemphigus (Hailey-Hailey), and porphyria cutanea tarda):</p><p class="depth0">More than 40 percent of the entire body or more than 40           60</p><p class="depth0">percent of exposed areas affected, or; constant or near-</p><p class="depth0">constant systemic therapy such as corticosteroids or other</p><p class="depth0">immunosuppressive drugs required during the past 12-month</p><p class="depth0">period.....................................................</p><p class="depth0">20 to 40 percent of the entire body or 20 to 40 percent of        30</p><p class="depth0">exposed areas affected, or; systemic therapy such as</p><p class="depth0">corticosteroids or other immunosuppressive drugs required</p><p class="depth0">for a total duration of six weeks or more, but not</p><p class="depth0">constantly, during the past 12-month period................</p><p class="depth0"></p><p class="depth0">At least 5 percent, but less than 20 percent, of the entire       10</p><p class="depth0">body, or at least 5 percent, but less than 20 percent, of</p><p class="depth0">exposed areas affected, or; intermittent systemic therapy</p><p class="depth0">such as corticosteroids or other immunosuppressive drugs</p><p class="depth0">required for a total duration of less than six weeks during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Less than 5 percent of the entire body or exposed areas            0</p><p class="depth0">affected, and; no more than topical therapy required during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7816 Psoriasis:</p><p class="depth0">More than 40 percent of the entire body or more than 40           60</p><p class="depth0">percent of exposed areas affected, or; constant or near-</p><p class="depth0">constant systemic therapy such as corticosteroids or other</p><p class="depth0">immunosuppressive drugs required during the past 12-month</p><p class="depth0">period.....................................................</p><p class="depth0">20 to 40 percent of the entire body or 20 to 40 percent of        30</p><p class="depth0">exposed areas affected, or; systemic therapy such as</p><p class="depth0">corticosteroids or other immunosuppressive drugs required</p><p class="depth0">for a total duration of six weeks or more, but not</p><p class="depth0">constantly, during the past 12-month period................</p><p class="depth0">At least 5 percent, but less than 20 percent, of the entire       10</p><p class="depth0">body, or at least 5 percent, but less than 20 percent, of</p><p class="depth0">exposed areas affected, or; intermittent systemic therapy</p><p class="depth0">such as corticosteroids or other immunosuppressive drugs</p><p class="depth0">required for a total duration of less than six weeks during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Less than 5 percent of the entire body or exposed areas            0</p><p class="depth0">affected, and; no more than topical therapy required during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7817 Exfoliative dermatitis (erythroderma):</p><p class="depth0">Generalized involvement of the skin, plus systemic               100</p><p class="depth0">manifestations (such as fever, weight loss, and</p><p class="depth0">hypoproteinemia), and; constant or near-constant systemic</p><p class="depth0">therapy such as therapeutic doses of corticosteroids,</p><p class="depth0">immunosuppressive retinoids, PUVA (psoralen with long-wave</p><p class="depth0">ultraviolet-A light) or UVB (ultraviolet-B light)</p><p class="depth0">treatments, or electron beam therapy required during the</p><p class="depth0">past 12-month period.......................................</p><p class="depth0">Generalized involvement of the skin without systemic              60</p><p class="depth0">manifestations, and; constant or near-constant systemic</p><p class="depth0">therapy such as therapeutic doses of corticosteroids,</p><p class="depth0">immunosuppressive retinoids, PUVA (psoralen with long-wave</p><p class="depth0">ultraviolet-A light) or UVB (ultraviolet-B light)</p><p class="depth0">treatments, or electron beam therapy required during the</p><p class="depth0">past 12-month period.......................................</p><p class="depth0">Any extent of involvement of the skin, and; systemic therapy      30</p><p class="depth0">such as therapeutic doses of corticosteroids,</p><p class="depth0">immunosuppressive retinoids, PUVA (psoralen with long-wave</p><p class="depth0">ultraviolet-A light) or UVB (ultraviolet-B light)</p><p class="depth0">treatments, or electron beam therapy required for a total</p><p class="depth0">duration of six weeks or more, but not constantly, during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Any extent of involvement of the skin, and; systemic therapy      10</p><p class="depth0">such as therapeutic doses of corticosteroids,</p><p class="depth0">immunosuppressive retinoids, PUVA (psoralen with long-wave</p><p class="depth0">ultraviolet-A light) or UVB (ultraviolet-B light)</p><p class="depth0">treatments, or electron beam therapy required for a total</p><p class="depth0">duration of less than six weeks during the past 12-month</p><p class="depth0">period.....................................................</p><p class="depth0">Any extent of involvement of the skin, and; no more than           0</p><p class="depth0">topical therapy required during the past 12-month period...7818 Malignant skin neoplasms (other than malignant melanoma):</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's 7801, 7802, 7803, 7804, or 7805), or impairment</p><p class="depth0">of function................................................</p><p class="depth0">Note: If a skin malignancy requires therapy that is</p><p class="depth0">comparable to that used for systemic malignancies, i.e.,</p><p class="depth0">systemic chemotherapy, X-ray therapy more extensive than to</p><p class="depth0">the skin, or surgery more extensive than wide local</p><p class="depth0">excision, a 100-percent evaluation will be assigned from</p><p class="depth0">the date of onset of treatment, and will continue, with a</p><p class="depth0">mandatory VA examination six months following the</p><p class="depth0">completion of such antineoplastic treatment, and any change</p><p class="depth0">in evaluation based upon that or any subsequent examination</p><p class="depth0">will be subject to the provisions of Sec.   3.105(e) of</p><p class="depth0">this chapter. If there has been no local recurrence or</p><p class="depth0">metastasis, evaluation will then be made on residuals. If</p><p class="depth0">treatment is confined to the skin, the provisions for a 100-</p><p class="depth0">percent evaluation do not apply.7819 Benign skin neoplasms:</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's 7801, 7802, 7803, 7804, or 7805), or impairment</p><p class="depth0">of function................................................7820 Infections of the skin not listed elsewhere (including</p><p class="depth0">bacterial, fungal, viral, treponemal and parasitic diseases):</p><p class="depth0">Rate as disfigurement of the head, face, or neck (DC 7800),</p><p class="depth0">scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis</p><p class="depth0">(DC 7806), depending upon the predominant disability.......7821 Cutaneous manifestations of collagen-vascular diseases not</p><p class="depth0">listed elsewhere (including scleroderma, calcinosis cutis, and</p><p class="depth0">dermatomyositis):</p><p class="depth0">More than 40 percent of the entire body or more than 40           60</p><p class="depth0">percent of exposed areas affected, or; constant or near-</p><p class="depth0">constant systemic therapy such as corticosteroids or other</p><p class="depth0">immunosuppressive drugs required during the past 12-month</p><p class="depth0">period.....................................................</p><p class="depth0"></p><p class="depth0">20 to 40 percent of the entire body or 20 to 40 percent of        30</p><p class="depth0">exposed areas affected, or; systemic therapy such as</p><p class="depth0">corticosteroids or other immunosuppressive drugs required</p><p class="depth0">for a total duration of six weeks or more, but not</p><p class="depth0">constantly, during the past 12-month period................</p><p class="depth0">At least 5 percent, but less than 20 percent, of the entire       10</p><p class="depth0">body, or at least 5 percent, but less than 20 percent, of</p><p class="depth0">exposed areas affected, or; intermittent systemic therapy</p><p class="depth0">such as corticosteroids or other immunosuppressive drugs</p><p class="depth0">required for a total duration of less than six weeks during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Less than 5 percent of the entire body or exposed areas            0</p><p class="depth0">affected, and; no more than topical therapy required during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7822 Papulosquamous disorders not listed elsewhere (including</p><p class="depth0">lichen planus, large or small plaque parapsoriasis, pityriasis</p><p class="depth0">lichenoides et varioliformis acuta (PLEVA), lymphomatoid</p><p class="depth0">papulosus, and pityriasis rubra pilaris (PRP)):</p><p class="depth0">More than 40 percent of the entire body or more than 40           60</p><p class="depth0">percent of exposed areas affected, and; constant or near-</p><p class="depth0">constant systemic medications or intensive light therapy</p><p class="depth0">required during the past 12-month period...................</p><p class="depth0">20 to 40 percent of the entire body or 20 to 40 percent of        30</p><p class="depth0">exposed areas affected, or; systemic therapy or intensive</p><p class="depth0">light therapy required for a total duration of six weeks or</p><p class="depth0">more, but not constantly, during the past 12-month period..</p><p class="depth0">At least 5 percent, but less than 20 percent, of the entire       10</p><p class="depth0">body, or at least 5 percent, but less than 20 percent, of</p><p class="depth0">exposed areas affected, or; systemic therapy or intensive</p><p class="depth0">light therapy required for a total duration of less than</p><p class="depth0">six weeks during the past 12-month period..................</p><p class="depth0">Less than 5 percent of the entire body or exposed areas            0</p><p class="depth0">affected, and; no more than topical therapy required during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7823 Vitiligo:</p><p class="depth0">With exposed areas affected.................................      10</p><p class="depth0">With no exposed areas affected..............................       07824 Diseases of keratinization (including icthyoses, Darier's</p><p class="depth0">disease, and palmoplantar keratoderma):</p><p class="depth0">With either generalized cutaneous involvement or systemic         60</p><p class="depth0">manifestations, and; constant or near-constant systemic</p><p class="depth0">medication, such as immunosuppressive retinoids, required</p><p class="depth0">during the past 12-month period............................</p><p class="depth0">With either generalized cutaneous involvement or systemic         30</p><p class="depth0">manifestations, and; intermittent systemic medication, such</p><p class="depth0">as immunosuppressive retinoids, required for a total</p><p class="depth0">duration of six weeks or more, but not constantly, during</p><p class="depth0">the past 12-month period...................................</p><p class="depth0">With localized or episodic cutaneous involvement and              10</p><p class="depth0">intermittent systemic medication, such as immunosuppressive</p><p class="depth0">retinoids, required for a total duration of less than six</p><p class="depth0">weeks during the past 12-month period......................</p><p class="depth0">No more than topical therapy required during the past 12-          0</p><p class="depth0">month period...............................................7825 Urticaria:</p><p class="depth0">Recurrent debilitating episodes occurring at least four           60</p><p class="depth0">times during the past 12-month period despite continuous</p><p class="depth0">immunosuppressive therapy..................................</p><p class="depth0">Recurrent debilitating episodes occurring at least four           30</p><p class="depth0">times during the past 12-month period, and; requiring</p><p class="depth0">intermittent systemic immunosuppressive therapy for control</p><p class="depth0">Recurrent episodes occurring at least four times during the       10</p><p class="depth0">past 12-month period, and; responding to treatment with</p><p class="depth0">antihistamines or sympathomimetics.........................7826 Vasculitis, primary cutaneous:</p><p class="depth0">Recurrent debilitating episodes occurring at least four           60</p><p class="depth0">times during the past 12-month period despite continuous</p><p class="depth0">immunosuppressive therapy..................................</p><p class="depth0">Recurrent debilitating episodes occurring at least four           30</p><p class="depth0">times during the past 12-month period, and; requiring</p><p class="depth0">intermittent systemic immunosuppressive therapy for control</p><p class="depth0">Recurrent episodes occurring one to three times during the        10</p><p class="depth0">past 12-month period, and; requiring intermittent systemic</p><p class="depth0">immunosuppressive therapy for control......................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7827 Erythema multiforme; Toxic epidermal necrolysis:</p><p class="depth0">Recurrent debilitating episodes occurring at least four           60</p><p class="depth0">times during the past 12-month period despite ongoing</p><p class="depth0">immunosuppressive therapy..................................</p><p class="depth0">Recurrent episodes occurring at least four times during the       30</p><p class="depth0">past 12-month period, and; requiring intermittent systemic</p><p class="depth0">immunosuppressive therapy..................................</p><p class="depth0">Recurrent episodes occurring during the past 12-month period      10</p><p class="depth0">that respond to treatment with antihistamines or</p><p class="depth0">sympathomimetics, or; one to three episodes occurring</p><p class="depth0">during the past 12-month period requiring intermittent</p><p class="depth0">systemic immunosuppressive therapy.........................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7828 Acne:</p><p class="depth0">Deep acne (deep inflamed nodules and pus-filled cysts)            30</p><p class="depth0">affecting 40 percent or more of the face and neck..........</p><p class="depth0">Deep acne (deep inflamed nodules and pus-filled cysts)            10</p><p class="depth0">affecting less than 40 percent of the face and neck, or;</p><p class="depth0">deep acne other than on the face and neck..................</p><p class="depth0">Superficial acne (comedones, papules, pustules, superficial        0</p><p class="depth0">cysts) of any extent.......................................</p><p class="depth0"></p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7829 Chloracne:</p><p class="depth0">Deep acne (deep inflamed nodules and pus-filled cysts)            30</p><p class="depth0">affecting 40 percent or more of the face and neck..........</p><p class="depth0">Deep acne (deep inflamed nodules and pus-filled cysts)            10</p><p class="depth0">affecting less than 40 percent of the face and neck, or;</p><p class="depth0">deep acne other than on the face and neck..................</p><p class="depth0">Superficial acne (comedones, papules, pustules, superficial        0</p><p class="depth0">cysts) of any extent.......................................</p><p class="depth0">Or rate as disfigurement of the head, face, or neck (DC</p><p class="depth0">7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">depending upon the predominant disability.7830 Scarring alopecia:</p><p class="depth0">Affecting more than 40 percent of the scalp.................      20</p><p class="depth0">Affecting 20 to 40 percent of the scalp.....................      10</p><p class="depth0">Affecting less than 20 percent of the scalp.................       07831 Alopecia areata:</p><p class="depth0">With loss of all body hair..................................      10</p><p class="depth0">With loss of hair limited to scalp and face.................       07832 Hyperhidrosis:</p><p class="depth0">Unable to handle paper or tools because of moisture, and          30</p><p class="depth0">unresponsive to therapy....................................</p><p class="depth0">Able to handle paper or tools after therapy.................       07833 Malignant melanoma:</p><p class="depth0">Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805),</p><p class="depth0">disfigurement of the head, face, or neck (DC 7800), or</p><p class="depth0">impairment of function (under the appropriate body system).</p><p class="depth0">Note: If a skin malignancy requires therapy that is</p><p class="depth0">comparable to that used for systemic malignancies, i.e.,</p><p class="depth0">systemic chemotherapy, X-ray therapy more extensive than to</p><p class="depth0">the skin, or surgery more extensive than wide local</p><p class="depth0">excision, a 100-percent evaluation will be assigned from</p><p class="depth0">the date of onset of treatment, and will continue, with a</p><p class="depth0">mandatory VA examination six months following the</p><p class="depth0">completion of such antineoplastic treatment, and any change</p><p class="depth0">in evaluation based upon that or any subsequent examination</p><p class="depth0">will be subject to the provisions of Sec.   3.105(e). If</p><p class="depth0">there has been no local recurrence or metastasis,</p><p class="depth0">evaluation will then be made on residuals. If treatment is</p><p class="depth0">confined to the skin, the provisions for a 100-percent</p><p class="depth0">evaluation do not apply.------------------------------------------------------------------------

(Authority: 38 U.S.C. 1155)
[67 FR 49596, July 31, 2002; 67 FR 58448, 58449, Sept. 16, 2002; 73 FR 54710, Oct. 23, 2008; 77 FR 2910, Jan. 20, 2012]</p><p class="depth0">The Endocrine System</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
